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FhCaBP3:  a Fasciola hepatica calcium binding protein with EF-
hand and dynein light chain domains 
 
Samantha Banford, Orla Drysdale, Elizabeth M Hoey, Alan Trudgett and David J 
Timson 
 
Highlights 
 
• FhCaBP3 contains two EF-hand motifs and a dynein light chain-like domain 
• Modelling predicts that calcium ion binding disrupts β-sheets in the DLC 
domain 
• FhCaBP3 binds Ca2+ and Mn2+ ions, but not Mg2+, Ba2+, Sr2+, Zn2+, Cd2+, Cu2+, 
Ni2+ 
• FhCaBP dimerises, but calcium ions reduce the amount of dimerisation 
• FhCaBP3 binds a range of calmodulin antagonists 
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Abstract 
A DNA sequence encoding a protein with predicted EF-hand and dynein light chain 
binding domains was identified in a Fasciola hepatica EST library.  Sequence 
analysis of the encoded protein revealed that the most similar known protein was the 
Fasciola gigantica protein FgCaBP3 and so this newly identified protein was named 
FhCaBP3.  Molecular modelling of FhCaBP3 predicted a highly flexible N-terminal 
region, followed by a domain containing two EF-hand motifs the second of which is 
likely to be a functioning divalent ion binding site.  The C-terminal domain of the 
protein contains a dynein light chain like region.  Interestingly, molecular modelling 
predicts that calcium ion binding to the N-terminal domain destabilises the β-sheet 
structure of the C-terminal domain.  FhCaBP3 can be expressed in, and purified from, 
Escherichia coli.  The recombinant protein dimerises and the absence of calcium ions 
appeared to promote dimerisation.  Native gel shift assays demonstrated that the 
protein bound to calcium and manganese ions, but not to magnesium, barium, zinc, 
strontium, nickel, copper or cadmium ions.  FhCaBP3 interacted with the calmodulin 
antagonists trifluoperazine, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide 
and chlorpromazine as well as the myosin regulatory light chain-binding drug 
praziquantel.  Despite sequence and structural similarities to other members of the 
same protein family from F. hepatica, FhCaBP3 has different biochemical properties 
to the other well characterised family members, FH22 and FhCaBP4.  This suggests 
that each member of this trematode calcium-binding family has discrete functional 
roles within the organism. 
 
Keywords:  EF-hand; trematode, calcium binding protein; liver fluke; DLC 
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1.  Introduction 
Calcium homeostasis is required in all living cells.  Consequently, elaborate molecular 
systems have evolved to control the flow of calcium ions in and out of cells.  Changes 
in calcium ion concentrations in cells also act as cellular signals and there are a 
number of proteins which sense these changes and transmit information to signalling 
pathways [1].  The best characterised of these is calmodulin, an approximately 17 kDa 
protein which has two globular heads joined by an α-helical linker.  Each globular 
head contains two EF-hand, calcium ion binding domains.  In each EF-hand, the ion is 
coordinated by a combination of six functional groups from the side chains and 
backbone of the protein [2-5].  Binding to calcium ions by the EF-hands induces a 
conformational change which results in the greater exposure of hydrophobic residues 
on the surface of the protein [6, 7].  These hydrophobic residues are important in 
interacting with some partner proteins and also with some drugs [6-10].  A number of 
calmodulin and calmodulin-like proteins have been characterised in trematodes.  
These include two calmodulins from the blood fluke Schistosoma mansoni (SmCaM1 
and SmCaM2) which show very high protein sequence similarity (>97%) to the 
human protein [11].  In the common liver fluke, Fasciola hepatica, there are at least 
three calmodulin-like proteins.  One, FhCaM1, an orthologue of SmCaM1, differs 
from human calmodulin by only two amino acid residues [12, 13].  The other two, 
FhCaM2 and FhCaM3, are more different at the sequence level (67% and 51% 
similarity respectively); however they are predicted to have similar overall structures 
to mammalian calmodulins [12, 13]. 
 
EF-hands are not only found in calmodulin and related proteins.  In trematodes there 
are at least two families of EF-hand containing proteins which are not present in their 
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mammalian hosts.  The first family is one containing small (approximately 8 kDa) 
proteins with one EF-hand and includes FH8 from F. hepatica, Sm8 from S. mansoni 
and SjCa8 from Schistosoma japonicum [14-16].  In the case of FH8, the calcium 
binding affinity has been shown to be low (Kd ~10-4 M) [16].  The second family 
consists of proteins which combine two EF-hand domains with a dynein light chain 
(DLC) domain.  The functions of these proteins have not been determined although 
some have been localised to the fluke’s tegument [17, 18].  Indeed, many species 
express several different proteins from this family suggesting either a requirement for 
redundancy or different functions for each family member.  Examples of these 
proteins include, the S. mansoni proteins Sm22.6 (SmTAL1), Sm21.7 (SmTAL3), 
Sm20.8 (SmTAL3) and Sm21.6 (SmTAL8), the Schistosoma japonicum protein 
Sj22.6, Schistosoma haematobium Sh22.6, the C. sinensus proteins CsTP31.8 and 
CsTegu21.6 and the Opisthorchis viverrini protein OvCaBP [19-27].  Recently, a 
family of related proteins in S. mansoni (SmTAL4 to SmTAL13) were identified by 
bioinformatics and partially characterised [28].  In Fasciola gigantica, four proteins 
from the family have been characterised thus far:  FgCaBP1, FgCaBP2, FgCaBP3 and 
FgCaBP4.  These proteins all bind calcium ions and FgCaBP1 is recognised by 
immune serum from infected rabbits, suggesting that the protein is secreted [17, 18].  
In the closely related liver fluke, F. hepatica, two family members have been 
characterised to date.  FH22 is the equivalent of FgCaBP1, undergoes calcium-
dependent conformational changes and is secreted from the fluke [29]. 
 
Interest in this group of calcium binding proteins which contain EF-hand and DLC-
like domains arises from their ability to induce by IgG and IgE-mediated immune 
responses in their hosts [23, 30-32] and from their potential as novel drug targets.  The 
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central importance of calcium homeostasis and calcium-mediated cellular signalling 
means that disruption of these networks is likely to result in deleterious effects on the 
fluke.  This family of proteins are particularly attractive as possible drug targets since 
they are unique to trematodes and thus molecules which antagonise their actions are 
less likely to interact with host molecules.  However, our current lack of detailed 
biochemical data prevents a full assessment of their potential as drug targets.  The 
need for novel therapeutics to control fasciolosis is urgent as resistance to the current 
drug of choice, triclabendazole, has now been reported worldwide [33-39].  Recently, 
we biochemically characterised FhCaBP4 (which has an identical protein sequence to 
FgCaBP4) and demonstrated that it binds calcium and some other divalent cations, 
undergoes a calcium-dependent conformational change which results in a more 
hydrophobic surface and dimerisation and that it interacts with the calmodulin 
antagonist W7 [40].  Here, we describe the biochemical characterisation of the third 
F. hepatica member of this family.  This protein is homologuous to FgCaBP3 and 
thus we have named it FhCaBP3. 
 
2.  Materials and Methods 
2.1  Cloning, expression and purification of FhCaBP3 
The coding sequence for FhCaBP3 was PCR-amplified using clone Fhep26e01 from a 
F. hepatica EST library as a template (available at:  
ftp://ftp.sanger.ac.uk/pub4/pathogens/Fasciola/hepatica/ESTs/) [41].  The amplicon 
was cloned into the Escherichia coli expression vector pET46 Ek/LIC (Merck, 
Nottingham, UK) according to the manufacturer's instructions.  (Note that this vector 
introduces bases coding for the amino acid sequence MAHHHHHHVDDDDK at the 
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5′ end of the coding sequence.)  Correct insertion into the vector was verified by PCR 
and by DNA sequencing (GATC, London, UK) of the insert. 
 
The expression vector was used to transform competent E. coli HMS174(DE3) and 
colonies resulting from this transformation were used to inoculate cultures (5 ml of 
Luria-Bertani medium (LB) supplemented with 100 µg.ml-1 ampicillin) which were 
grown at 37 °C overnight with shaking.  Each culture was then diluted into 1 l of LB 
(supplemented with 100 µg.ml-1 ampicillin), grown until A600 reached 0.6 to 1.0 
(typically 3-4h), induced with 1 mM IPTG and then grown for further 2 h.  After this 
time, the cells were collected by centrifugation (4200 g for 15 min), resuspended in 
approximately 20 ml of buffer R (50 mM Hepes-OH, pH 7.5, 150 ml sodium chloride, 
10% (v/v) glycerol) and frozen at -80 °C. 
 
These cell suspensions were thawed and the cells disrupted by sonication on ice (three 
times 100 W pulses of 30 s duration with 30-60 s gaps inbetween for cooling).  Solid 
debris was removed immediately by centrifugation (22,000 g for 15 min at 4 °C) and 
the supernatant applied to a nickel-agarose column (1 ml, His-Select,Sigma, Poole, 
UK) which had been pre-equilibrated in buffer A (as buffer R, except 500 mM sodium 
chloride).  The supernatant was allowed to pass through under gravity and the column 
was then washed with 20 ml buffer A.  FhCaBP3 was eluted with three 2 ml washes 
with buffer B (buffer A supplemented with 250 mM imidazole) and its purity verified 
by SDS-PAGE.  Protein containing fractions were dialysed overnight at 4 °C against 
buffer D (buffer R supplemented with 1 mM DTT).  The concentration of FhCaBP3 
was determined by the method of Bradford [42] using BSA as a control.  The protein 
solution was divided into aliquots (50-100 µl) and stored at -80 °C until required. 
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2.2  Bioinformatics and Molecular Modelling 
Multiple sequence alignments were constructed using ClustalW [43, 44] and an 
unweighted pair group method with arithmetic mean (UPGMA) tree was generated 
using MEGA 5.05 [45]. 
 
A molecular model of FhCaBP3 was constructed by using Phyre2 
((http://www.sbg.bio.ic.ac.uk/phyre2 [46]) in the “intensive” mode.  This model was 
then minimised and computationally solvated using YASARA 
(http://www.yasara.org/minimizationserver.htm [47]).  Potential ligand binding sites 
in this model were identified using 3dligandsite 
(http://www.sbg.bio.ic.ac.uk/3dligandsite [48]).  A calcium ion was modelled into the 
structure using Reps1 EH domain (PDB ID:  1FI6 [49]) as a template and the 
resulting structure re-minimised using YASARA.  The final, calcium bound and 
calcium free, minimised models are provided as supplementary data to this paper. 
 
2.3  Native gel electrophoresis 
FhCaBP3 (90 µM) was mixed with 1 mM EGTA and 1 mM DTT and the mixture 
supplemented with divalent metal ions (2 mM) as required in a total volume of 10 µl.  
Note that EGTA was routinely included in these mixtures to remove any calcium ions 
which had associated with FhCaBP3 during the expression and purification process.  
(This has been previously observed with other F. hepatica calcium binding proteins 
[13, 40]).  Mixtures were incubated at room temperature for 5 min and then 10 µl 
native gel loading buffer (120 mM Tris pH 6.8, 20% (v/v) glycerol, 5% (w/v) 
bromophenol blue, 1% (w/v) DTT) was added.  Electrophoresis was carried out using 
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10% polyacrylamide gels (pH 8.8), with a running buffer of 25 mM Tris-HCl, 250 
mM glycine, pH 8.8 at 20 mA (constant current) for 40 min.  Gels were stained with 
Coomassie blue (dissolved in 45 % (v/v) ethanol, 10 % (v/v) glacial acetic acid) and 
destained in 0.75 %(v/v) glacial acetic acid/ 0.5 %(v/v) ethanol. 
 
2.4  Fluorescence measurements 
Intrinsic fluorescence spectra of FhCaBP3 (2 µM; supplemented with 1 mM DTT in a 
total volume of 150 µl) were recorded from 310 to 400 nm using a Spectra Max 
Gemini XS fluorescence plate-reader and SOFTmax PRO software in a 
FluoroNunc™ black 96-well plate using an excitation wavelength of 280 nm.  For 8-
anilinonaphthalene-1-sulphonate (ANS) displacement assays, FhCaBP3 (9 µM) was 
incubated for 1 h at 37 °C with either 2 mM CaCl2/1 mM EGTA or 1 mM EGTA in 
the presence of 20 µM ANS in a total volume of 150 µl.  The negative control 
contained 10 mM HEPES pH 8.8 and 20 µM ANS.  The fluorescence spectrum (440 
nm to 510 nm; excitation wavelength 350 nm) was then recorded. 
 
2.5  Crosslinking 
FhCaBP3 (30 µM) was incubated with bis(sulfosuccinimidyl) suberate (BS3, 80 or 
800 µM) in the presence of either 1 mM EGTA or 1mM EGTA/2 mM calcium 
chloride for 30 min at 37 °C.  Products were then analysed by 10% SDS-PAGE.  
Crosslinking with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) was carried out as previously described [40]. 
 
2.6  Analytical gel filtration 
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FhCaBP3 (200 µl of a 380 µM solution) in the presence of either 2 mM calcium 
chloride or 2 mM EGTA was chromatographed on a Sephacryl S-300 (Pharmacia) 
column (total volume, Vt=55 ml; void volume, V0=17.5 ml) at a flow rate of 1 ml.min-
1
.  The column was equilibrated and developed in buffer G (50 mM Tris-HCl, 17 mM 
Tris base, 150 mM sodium chloride, pH 7.4 [50]) supplemented with either 2 mM 
calcium chloride or 2 mM EGTA as appropriate.  Fractions (1 ml) were collected and 
analysed for protein content by measuring the absorbance at 280 nm.  Standard 
proteins (albumin, 67 kDa and ribonuclease A, 13.7 kDa) were used to calibrate the 
column.  Their elution volumes (Ve) were used to calculate Kav according to the 
equation: 
et
e
av VV
VV
K
−
−
=
0
 
Molecular masses were estimated by making use of the inverse, linear correlation 
between Kav and the logarithm of the molecular mass [51]. 
 
2.7  Limited proteolysis 
FhCaBP3 (40 µM) was incubated in the presence of drug (250 µM) and 2 mM 
calcium chloride for 5 min at 37 °C. After this time chymotrypsin (200 nM) was 
added and the mixture incubated for 30 min at 37 °C.  Products were resolved on 15% 
SDS-PAGE. 
 
3.  Results 
3.1  FhCaBP3:  sequence analysis and predicted structure 
The coding sequence of FhCaBP3 codes for a 210 amino acid residue protein of 
molecular mass approximately 26 kDa and an estimated isoelectric point of 6.4.  The 
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N-terminal part (residues 1-98) of the protein is predicted to form two EF-hand 
domains and the C-terminal part (residues 118-210) a DLC-like domain (figure 1a).  
The sequence has been submitted to the GenBank database with the accession number 
JX070093.  A BLAST search revealed that the most similar known protein is the F. 
gigantica protein FgCaBP3 from which it differs by only two amino acid residues.  A 
BLAST search revealed that the most similar known protein is the F. gigantica 
protein FgCaBP3 from which it differs by only two amino acid residues.  An 
UPGAMA phylogenetic analysis shows that the sequence clusters with FgCaBP3, 
FH22 and FgCaBP1 (figure 1b). 
 
A molecular model of the protein predicted that it is organised into two domains 
joined by a flexible linker (figure 2a).  The N-terminal domain contains two EF-hand 
motifs.  Prediction of the ligand binding properties of the protein, using 3DLigandSite 
predicted that the second of these EF-hands can be occupied by a calcium ion.  The 
two highest matches used for modelling of the EF-hand domain, the EF-hand domain 
of human RASEF (PDB ID: 2PMY, unpublished) and the Reps1 EH domain 
(PDB ID:  1FI6 [49]) have two and one calcium ions bound respectively.  
Therefore, a calcium ion was modelled at the second EF-hand only (figure 2b).  
In EF-hands, six residues contribute to the coordination of the ion.  These are 
designated the X,Y, Z, -Y, -X and –Z residues and analysis of EF-hand proteins 
has identified consensus residues at these positions [52].  In both EF-hands in 
FhCaBP3, the consensus is largely observed, with the greatest deviation at the 
fourth coordinating position (-Y) which is most commonly a threonine (figure 
2c,d).  In the first EF-hand this residue is a serine (which is rarely seen at this 
position in EF-hands) and in the second EF-hand it is a lysine, which while 
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observed occasionally in EF-hands, introduces a positive charge into the motif.  
However, the modelled structure shows that the positively charged lysine side 
chain is directed away from the calcium ion (figure 2d). 
 
Dynein light chains are typically rich in β-sheets [53, 54].  Interestingly, 
following minimisation of the modelled structure of FhCaBP3 in the absence of 
calcium ions, two of the four β-strands seen in dynein light chains were modelled 
as random coil structures (figure 2a).  In the presence of a modelled calcium ion, 
all four β-strands were converted to a random coil structure (figure 2b).  
However, in the presence of a modelled magnesium ion, only two of the strands 
were converted to random coil, in a similar fashion to the ion-free protein.  
Modelling a manganese ion into the binding site resulted in complete disruption 
of two of the β-sheets and partial disruption of the remaining two (data not 
shown). 
 
FhCaBP3 and FgCaBP3 differ from other members of the family in that they 
have an extended N-terminal region (amino acids 1 to 17).  In the model, this is 
predicted to form a random coil and wrap around the C-terminal, DLC-like 
domain.  Estimation of the flexibility of the polypeptide chain predicted that this 
region is, by far, the most flexible part of the protein suggesting that it can adopt 
multiple conformations including the one shown in the model (figure 2e). 
 
3.2  Expression, purification and dimerisation of FhCaBP3 
FhCaBP3 could be expressed in, and purified from E. coli cells.  Typical yields were 
approximately 20 mg protein per litre of bacterial cell culture (figure 3).  Interestingly, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 12 
when the protein was resolved by SDS-PAGE a fraction of the protein appeared to run 
at twice the expected molecular mass.  This suggests that some of the protein formed 
dimers which are resistant to separation by SDS and heat treatment (figure 3).  Heat 
and SDS-resistant oligomerisation has been observed in a number of other proteins, 
for examples see [55-59].  The intensity of this band was not reduced by 
supplementation of the loading buffer with additional DTT (2 mM, data not shown). 
 
The ability of FhCaBP3 to form homodimers was further investigated using chemical 
crosslinking with the reagent BS3.  Resolution of the crosslinked products by SDS-
PAGE revealed a band corresponding to a FhCaBP3 homodimer in the presence and 
absence of calcium ions.  However, the intensity of this band was greater in the 
absence of calcium ions (figure 4a).  Similar results were seen with the reagent EDC 
(data not shown).  A change in molecular mass was also detected by gel filtration 
chromatography.  The protein eluted at a larger volume in the presence of 2 mM 
EGTA, than in the presence of 2 mM calcium chloride (figure 4b).  The molecular 
mass of the protein in the presence of calcium ions was estimated by this method to be 
21 kDa compared to 38 kDa in their absence; these values are consistent with 
dimerisation being promoted by the absence of calcium ions.  Furthermore, the peak 
observed in the absence of free calcium ions was much sharper and more symmetrical 
than the one observed the presence suggesting conformational heterogeneity in the 
calcium-bound state (figure 4b). 
 
3.3  FhCaBP3 binds calcium and other divalent cations 
Ion binding often alters the overall conformation and charge of proteins and thus it 
can be detected by changes of mobility in native gel electrophoresis.  In this 
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technique, the mobility of proteins is determined by the charge, hydrodynamic volume 
and shape of the molecule; all three of these may be affected by the binding of 
divalent cations.  FhCaBP3’s electrophoretic mobility was reduced in the presence of 
calcium ions (figure 5a).  Managanese ions were also able to reduce the mobility, 
demonstrating that the protein can also bind these species.  However, no binding to 
magnesium, barium, zinc, strontium, nickel, copper and cadmium ions was detected 
(figure 5a). 
 
In many calcium ion binding proteins, including FhCaBP4, calcium ion binding 
increases the surface hydrophobicity [40].  This change can be detected through 
increased interaction, and consequent enhanced fluorescence, of the probe 8-
anilinonaphthalene-1-sulphonate (ANS) [16, 60-62].  However, in the case of 
FhCaBP3 no such change in ANS fluorescence could be detected (data not shown).  
Measurement of the intrinsic fluorescence of the protein demonstrated a modest 
enhancement in the fluorescence intensity in the presence of calcium (figure 5b) 
providing further evidence for interaction with this ion. 
 
4.3  FhCaBP3 interacts with calmodulin antagonists 
The ability of FhCaBP3 to interact with calmodulin binding drugs was probed by 
limited proteolysis and fluorescence spectroscopy.  Limited proteolysis with 
chymotrypsin degrades FhCaBP3 into several fragments (figure 6a, lane -).  This 
digestion pattern is not greatly affected by the presence of 1%(v/v) DMSO, the 
solvent used for the drugs.  The calmodulin antagonists trifluoperazine (TFP) and N-
(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W7) as well as the myosin 
regulatory light chain binding drug praziquantel (PZQ) all altered the digestion 
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pattern; the calmodulin antagonist chlorpromazine (CPZ) did not (figure 6a).  The 
intrinsic fluorescence spectrum of FhCaBP3 was not greatly altered by 1%(v/v) 
DMSO or 250 µM PZQ.  However, TFP and CPZ both caused a considerable 
quenching of the fluorescence emission intensity and a modest increase in the 
wavelength of maximum emission intensity (figure 6b).  Note that it was not possible 
to measure the effects of W7 by this method due to the fluorescence of this compound 
which overlapped that of the protein. 
 
4.  Discussion 
FhCaBP3 belongs to a family of trematode proteins which contain EF-hand and 
dynein light chain-like domains.  To date, this family appears to be unique to 
trematodes and thus is of particular interest in understanding the biochemistry of this 
class of parasitic organisms.  Although there is considerable sequence (and thus, most 
likely, structural) similarity between members of this group of proteins, biochemical 
differences have been identified. 
 
The other members of the family from F. hepatica which have been well 
characterised at the biochemical level are FH22 and FhCaBP4 [29, 40].  Compared to 
these, FhCaBP3 has an N-terminal extension which is predicted to be largely 
unstructured.  The function of this region is currently unclear, but intrinsically 
unstructured regions of proteins are often involved in the interaction with other 
proteins or with small molecules.  Alternatively, they can provide sites for irreversible 
regulation of activity through proteolytic degradation [63, 64].  The predicted effects 
of calcium (or manganese) ion binding are also interesting.  Dynein light chains 
dimerise through a β-sheet structure which stretches across the two monomers.  In 
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FhCaBP3, calcium ion binding is predicted to disrupt the β-sheet structure of the 
dynein light chain-like domain which may disrupt, or reduce, the tendency of the 
protein to homodimerise (figure 2b).  This is consistent with the observation that less 
protein-protein crosslinking and that the molecular mass as estimated by gel filtration 
doubled in the absence of calcium ions (figure 4). 
 
Unlike FhCaBP4, binding of calcium ions to FhCaBP3 does not result in a 
measurably more hydrophobic protein surface.  Nevertheless, it does induce 
conformational changes as indicated by both mobility shifts in native gel 
electrophoresis and intrinsic fluorescence changes.  FhCaBP3 interacts with a number 
of drugs which bind to calmodulin and the related protein myosin regulatory light 
chain.  Their mode of interaction appears to differ.  TFP, W7 and PZQ alter the 
limited proteolysis pattern, suggesting alterations to the conformation of surface-
exposed loops; CPZ has no such effect.  However, CPZ and TFP, but not PZQ, 
quench the fluorescence emission of FhCaBP3 suggesting that these compounds 
either bind in the vicinity of tryptophan residues or bind in a way which results in 
alterations to the protein structure in the environment of at least one tryptophan 
residue.  Previously it has been suggested that PZQ antagonises voltage-gated calcium 
channels and it interacts with myosin regulatory light chain in schistosomes [65, 66].  
The observation that it interacts with FhCaBP3 adds to the list of potential targets of 
this drug. 
 
The cellular roles of this group of proteins remain unclear.  An early report on S. 
mansoni Sm20.8 indicated that the protein bound directly to a dynein light chain 
(SmDLC), presumably through the dynein light chain-like domain [25].  That the N-
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terminal domain can interact with calcium ions suggests that the proteins may have a 
role in sensing and responding to this ion in some signalling process.  Given that 
dyneins function as microtubule motor proteins, disruption of these signalling 
pathways is likely to be detrimental to trematodes in a manner similar to that seen 
with benzimidazoles or tubulozole C [67].  Thus, selective antagonism of members of 
this family may offer a realistic and novel therapeutic approach to the treatment of 
fasciolisis and other trematode infections.  Furthermore, the different biochemical 
properties of family members suggest that they have discrete functional roles within 
the organism.  Determining these roles should be a key aim of further research in this 
area. 
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Figure legends 
Figure 1:  Sequence of FhCaBP3 and its analysis  (a) The amino acid sequence of 
FhCaBP3 with the EF-hands underlined and  the potential calcium coordinating 
residues shown in bold.  (b) An UPGMA tree showing the similarities of sequences of 
selected trematode proteins which share the same domain organisation as FhCaBP3.  
Figures at the nodes give the percentage level of bootstrap support for the node after 
1000 reiterations.  Accession numbers:  CsTegAnt (GAA56892); OvCaBP (no 
accession number assigned [24]); CsTegu21.6 (AEI69651); FhCaBP4 (GAA56892); 
FgCABP4 (AEX92829); FgCaBP3 (AEX92828); FgCaBP2 (no accession number 
assigned [18]); FH22 (CAA06036); FgCaBP1 (AAZ20312); Sm21.7 or SmTAL2 
(P32070); SmTAL12 (CCE94320); Sj22.6 (AAB52407); Sm22.6 or SmTAL1 
(AAA29922); Sh22.6 (AAW49250); Sm21.6 or SmTAL8 (ACL54849); SmTAL13 
(CCE94321); SmTAL7 (CCE94316); SmTAL6 (CCE94315); SmTAL4 (ACN82431); 
Sm20.8 or SmTAL3 (AAC79130); SmTAL11 (CCE94319); SmTAL5 (CCE94314); 
SmTAL9 (CCE94317); SmTAL10 (CCE94318).  (Cs, Clonorchis sinenis; Ov, 
Opisthorchis viverrini; Fg, Fasciola gigantica; Fh, Fasciola hepatica; Sm, 
Schistosoma mansoni; Sj, Schistosoma japonicum; Sh, Schistosoma haematobium.) 
 
Figure 2:  Predicted structure of FhCaBP3 (a) Modelled structure of FhCaBP3 in 
the absence of a bound divalent cation.  The N- and C-termini are indicated by N and 
C respectively.  (b)  Modelled structure of FhCaBP3 in the presence of a calcium ion 
bound at the second EF-hand (shown as a sphere).  Note the loss of the β-sheet 
structure in the C-terminal dynein light chain-like domain.  (c) The structure of the 
first EF-hand domain showing the potential ion coordinating residues.  (d)  The 
structure of the second EF-hand binding domain with a calcium ion (sphere) 
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coordinated.  Structural representations in (a)-(d) were made using PyMol 
(www.pymol.org).  (e)  A plot of the polypeptide backbone flexibility (estimated as 
described in Materials and Methods) against residue number. 
 
Figure 3:  Expression and purification of FhCaBP3  SDS-PAGE (10%) showing 
the expression and purification of recombinant FhCaBP3.  M, molecular mass 
markers (sizes in kDa are shown to the left of the gel); U, extract from cells prior to 
induction; I, extract from cells 2 h after induction; S, soluble material following 
sonication of the cells; F, material which flowed through the column; W, material 
which was removed from the column by washing with buffer A; E1, E2 and E3, the 
first, second and third elutions with buffer B. 
 
Figure 4:  Dimerisation of FhCaBP3 is promoted by the absence of calcium ions 
(a)  SDS-PAGE (10%) showing the crosslinking of FhCaBP3 (35 µM) with BS3.  M, 
molecular mass markers (sizes in kDa are shown to the left of the gel).  For Ca2+, - 
represents the presence of 1 mM EGTA and + the presence of 1 mM EGTA and 2 
mM calcium chloride.  For BS3, - represents the absence of the reagent, + the presence 
of 80 µM and ++ the presence of 800 µM.  (b) Analytical gel filtration elution profile 
of FhCaBP3 (380 µM) in the presence of either 2 mM calcium chloride (filled 
squares, +Ca2+) or 2 mM EGTA (open squares, -Ca2+). 
 
Figure 5:  Divalent ion binding by FhCaBP3  (a) FhCaBP3 (90 µM) was resolved by 
10% native polyacrylamide gel electrophoresis in the presence of 1 mM EGTA, 1 mM 
DTT and various ions (2 mM) as indicated.  C, FhCaBP3 without added ions; E, 
FhCaBP3 in the presence of EGTA only.  The altered mobility in the presence of 
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calcium and manganese ions results from binding to these ions.  (b)  Fluorescence 
emission spectrum of FhCaBP3 (2 µM) in the presence of 1 mM EGTA (- Ca2+) and 
in the presence of 1 mM EGTA/2 mM calcium chloride (+ Ca2+).  Each point 
represents the mean of three independent measurements. 
 
Figure 6:  Calmodulin antagonists interact with FhCaBP3  (a) SDS-PAGE (15%) 
showing the effects of various drugs (250 µM) on the digestion of FhCaBP3 (40 µM) 
by chymotrypsin (200 nM) in the presence of 2 mM calcium chloride.  M, molecular 
mass markers (sizes in kDa are shown to the left of the gel); U, undigested FhCaBP3; 
C, chymotrypsin only; -, FhCaBP3 digested in the absence of any drugs; DMSO, 
FhCaBP3 digested in the presence of 1% (v/v) DMSO.  (b) Fluorescence emission 
spectra of FhCaBP3 (3 µM) in the presence of EGTA (1 mM), calcium chloride (2 
mM), DTT (1 mM) and various drugs (130 µM).  A control spectrum in the presence 
of 1%(v/v) DMSO was also recorded.  Each point represents the mean of three 
independent determinations and the error bars the standard deviations of these means. 
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